AMPE Stock UPDATES Ampio Pharmaceutical (AMPE) 3.65 09/17/2014

New Post Public Reply Private Reply Replies (0) Message Board

Sep 17, 2014 at 1:57 AM

Ampio Pharmaceutical (AMPE) 3.65 $AMPE

Ampio Pharmaceuticals Announces Webcast for Annual Shareholder Meeting
PR Newswire - Mon Sep 15, 1:00PM CDT
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) a clinical trial stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options, today announced that its September 20, 2014 annual meeting of shareholders will be shared live through a webcast. This webcast will provide audio throughout supplemented by video of the slides and videos supporting presentations by management as well as the direct reports of clinical investigators that have participated in past (single injection) and ongoing (multiple injection) AmpionTM clinical trials.

Health Care Sector Stocks Technical Review - Ampio Pharma, InterMune, Biogen Idec, Hologic, and CareFusion Corp.
PR Newswire - Mon Sep 15, 7:40AM CDT
On Friday, September 12, 2014, the NASDAQ Composite ended at 4,567.60, down 0.53%, the Dow Jones Industrial Average finished the day 0.36% lower at 16,987.51, and the S&P 500 closed at 1,985.54, down 0.60%. The losses were broad based as all the ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 736.69, down 0.69%, while the index has advanced 2.86% in the last one month. Investor-Edge has initiated coverage on the following equities: Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE), InterMune Inc. (NASDAQ: ITMN), Biogen Idec Inc. (NASDAQ: BIIB), Hologic Inc. (NASDAQ: HOLX), and CareFusion Corporation (NYSE: CFN). Free research on these five companies can be accessed at:

Another Mixed Stock Market Day but Indexes May Go Higher Friday
at The Street - Thu Sep 11, 4:24PM CDT
The stock indexes shed most of their losses Thursday as the indexes position themselves for another move higher.

U.S. Stocks Stage Unimpressive Rebound as Apple Leads the Way
at The Street - Wed Sep 10, 4:42PM CDT
The major stock indexes rebounded on Wednesday but will it continue Thursday?

Simple Math Shows Ampio Knee Arthritis Drug is No Better Than Saline
at The Street - Wed Sep 03, 11:04AM CDT
With Ampion failure, Ampio's pipeline is worthless.

Ampio Pharmaceuticals (AMPE): Today's Weak On High Volume Stock
at The Street - Wed Sep 03, 9:05AM CDT
Trade-Ideas LLC identified Ampio Pharmaceuticals (AMPE) as a weak on high relative volume candidate

Update on the Phase III multicenter, double-blind STEP study of Ampion(TM) for Osteoarthritis of the Knee
PR Newswire - Tue Sep 02, 6:56AM CDT
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced an update on the phase III, multicenter, double-blind STEP study of Ampion(TM) for osteoarthritis of the knee.

Allergan Seeks Court Order to Stop Valeant, Affiliates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 3:40PM CDT
Allergan (AGN) is being relentlessly pursued by Valeant Pharmaceuticals International (VRX) since Apr 2014.

Robbins Arroyo LLP is Investigating the Officers and Directors of Ampio Pharmaceuticals, Inc. (AMPE) on Behalf of Shareholders
GlobeNewswire - Thu Aug 28, 1:42PM CDT
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Ampio Pharmaceuticals, Inc. breached their fiduciary duties to shareholders. Ampio develops therapies for the treatment of prevalent inflammatory conditions in the United States.

Letter to the Ampio Shareholders in Regard to the STEP Study and Ampio's plans for the Ampion(TM) BLA
PR Newswire - Mon Aug 25, 6:56AM CDT
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today is issuing this response to the most commonly asked questions in regards to the STEP study and clarify its plan for moving forward with Ampion(TM) for osteoarthritis of the knee.

Ampio Shares Fall as STEP Study on Ampion Gets Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 3:35PM CDT
Shares of Ampio Pharmaceuticals, Inc. (AMPE) declined significantly after the company announced that there will be a delay in the data analysis of the STEP Study on its candidate Ampion.

Weak On High Volume: Ampio Pharmaceuticals (AMPE)
at The Street - Fri Aug 22, 1:47PM CDT
Trade-Ideas LLC identified Ampio Pharmaceuticals (AMPE) as a weak on high relative volume candidate

Why Ampio Pharmaceuticals (AMPE) Stock Hit a One-Year Low Today
at The Street - Fri Aug 22, 10:18AM CDT
Ampio Pharmaceuticals (AMPE) plunged to a 52-week low on Friday, one day after the biopharmaceutical company announced a major setback to a study on its osteoarthritis drug Ampion.

Why Ampio Pharmaceuticals (AMPE) Stock Is Plummeting Today
at The Street - Thu Aug 21, 11:34AM CDT
Ampio Pharmaceuticals (AMPE) plummeted Thursday after the company announced a major setback to a study on its osteoarthritis drug Ampion.

Ampio: The Freezer Killed My Osteoarthritis Drug
at The Street - Thu Aug 21, 9:23AM CDT
Ampio Pharmaceuticals is blaming a mini Polar Vortex for blowing up a pivotal study of its osteoarthritis drug Ampion.

Ampio reports that due to temperature deviations below product specifications during shipments to the Ampion(TM) STEP Study clinical sites, release of data will be delayed
PR Newswire - Thu Aug 21, 6:56AM CDT
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced a delay in the data analysis of the STEP Study due to the discovery by the independent Clinical Research Organization (CRO) that the study drug (both AmpionTM and the placebo) were, during shipment to the clinical sites, exposed to lower temperatures than permitted by the drug specifications.

Ampio's Ampion Positive in Open Label Study, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 4:33PM CDT
Ampio Pharmaceuticals, Inc.'s (AMPE) announced positive results from the open label portion of a study on multiple injections of Ampion for osteoarthritis of the knee.

Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting
PR Newswire - Tue Aug 19, 6:56AM CDT
Luoxis Diagnostics, Inc., a subsidiary of Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), today announced an upcoming presentation at the 73rd Annual Meeting of the American Academy of Surgical Trauma (AAST) and Clinical Congress of Acute Care Surgery in Philadelphia, Pennsylvania that will be held September 10-13, 2014. The presentation will report results from a recently completed five-year prospective clinical trial conducted using Luoxis' proprietary RedoxSYS oxidation-reduction potential (ORP) diagnostic platform to assess prognosis and outcomes in patients with traumatic brain injury.

Ampio Announces Very Positive Results of the Open Label Portion of the Multiple Intra-articular Injections Study of Ampion(TM) in Patients with Osteoarthritis of the Knee at Week Six of the Trial
PR Newswire - Mon Aug 18, 7:00AM CDT
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the 6 weeks results of the open label portion of the multiple injections of Ampion(TM) into the knees of patients (n=7) with osteoarthritis (OA).

Biotech Stock Mailbag: Exact Sciences, Galena, Amgen
at The Street - Fri Aug 15, 6:22AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

SmallRig Boosts Art-Driven Innovation in AI Era

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Luvme Hair Offers Wig Variety for Winter Fashion

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Uber Data Breach: Class Action Investigation Begins

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

PASCAL's Holiday Gift Edit: Timeless Watches Shine

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

El Pollo Loco Faces Class Action Over Wage Practices

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

MV Transportation Celebrates Leadership Nomination for FTA

MV Throws Support Behind Aesch for FTA Role In this wild world where public transit feels the heat from financial burdens, MV Transportation's recent move to support Mark Aesch for the Federal Transit Administration's top spot isn’t just a nod of approval—it's a full-blown trumpet blast. They're not just doling out a basic endorsement here; they're practically waving...

Breakthrough T1D Pushes Global T1D Awareness Forward

Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...